Ebola: We Have Find The Medicine,

A needle-free Ebola vaccine protects monkeys 100 percent of the time from the virus, even a year after they’ve been vaccinated, researchers reported Monday.

The vaccine uses a common cold virus genetically engineered to carry a tiny piece of Ebola DNA. Sprayed up the nose, it saved all nine monkeys tested for infection.

But now the research is dead in the water without funding, Maria Croyle of the University of Texas at Austin’s College of Pharmacy said.

“Now we are at the crossroads, trying to figure out where to get the funding and resources to continue,” Croyle told NBC News.

It’s only a small study, but the results are encouraging, said Croyle, whose findings are published in the journal Molecular Pharmaceutics and being discussed at the American Association of Pharmaceutical Scientists meeting in San Diego this week.


Human trials underway for Ebola vaccine testingTODAY
 
The logical next stage would be tests in people. Croyle says she’s seeking either a drug company, or the federal government, or both, to work with her team. The U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has a vaccine development center that’s worked on other Ebola vaccines.

Several Ebola vaccines have been in the works for years. But until this current epidemic in West Africa, which has infected more than 13,000 people, there wasn’t a real push to bring such a vaccine to market and the main source of funding was U.S. biodefense programs aimed at protecting against a biological attack.
Source